PMID- 17386416
OWN - NLM
STAT- MEDLINE
DCOM- 20070613
LR  - 20111117
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 7
IP  - 5
DP  - 2007 May
TI  - Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of 
      Pseudomonas aeruginosa sepsis in mice.
PG  - 687-700
AB  - We investigated the efficacy of amino acids 55-76 of the synthetic shrimp 
      anti-lipopolysaccharide factor peptide (SALF(55-76) cyclic peptide), the 
      C-terminal part of the shrimp anti-lipopolysaccharide factor. This study was 
      conducted to elucidate the effects of the antiseptic action of this peptide. The 
      SALF(55-76) cyclic peptide was tested against bacterial clinical isolates and 
      showed broad-spectrum antimicrobial activity. Transmission electron microscopic 
      (TEM) examination of SALF(55-76) cyclic peptide-treated Pseudomonas aeruginosa 
      showed that severe swelling preceded cell death and breakage of the outer 
      membrane; the intracellular inclusion was found to have effluxed extracellularly. 
      When mice were treated with the SALF(55-76) cyclic peptide before bacterial 
      challenge with P. aeruginosa, the peptide highly protected mice against death by 
      sepsis. The P. aeruginosa recovered from SALF(55-76) cyclic peptide-treated mice 
      after 4 h exhibited reduced bacterial growth similar to that recovered from 
      vancomycin-treated mice. In addition, the syntheses of inflammatory cytokines, 
      such as interleukin (IL)-2, IL-4, IL-10, IL-12, IL-13, interferon-gamma, and 
      tumor necrosis factor [TNF]-alpha, were significantly upregulated 4 h after 
      SALF(55-76) cyclic peptide treatment except for IL-4 in the liver. The 
      expressions of Toll-like receptor 4 (Tlr4), Irf3, myd88, and Tram, were 
      considerably elevated, but only Tlr4 existed in the spleen 4 h after SALF(55-76) 
      cyclic peptide treatment. The prophylactic administration of SALF(55-76) cyclic 
      peptide was begun the TNF-alpha response in comparison to untreated mice by an 
      ELISA analysis. Due to its multifunctional properties, the SALF(55-76) cyclic 
      peptide may become an important prophylaxis against and therapy for bacterial 
      infectious diseases, as well as for septic shock.
FAU - Pan, Chia-Yu
AU  - Pan CY
AD  - Marine Research Station, Institute of Cellular and Organismic Biology, Academia 
      Sinica, 23-10 Dahuen Road, Jiaushi, Ilan 262, Taiwan.
FAU - Chao, Tsung-Tai
AU  - Chao TT
FAU - Chen, Jian-Chyi
AU  - Chen JC
FAU - Chen, Jyh-Yih
AU  - Chen JY
FAU - Liu, Wei-Chen
AU  - Liu WC
FAU - Lin, Cheng-Hui
AU  - Lin CH
FAU - Kuo, Ching-Ming
AU  - Kuo CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070207
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Arthropod Proteins)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Messenger)
RN  - 0 (shrimp anti-lipopolysaccharide factor cyclic peptide (55-76))
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Anti-Infective Agents/*pharmacology
MH  - Arthropod Proteins
MH  - Bacteria/drug effects
MH  - Cell Line, Tumor
MH  - Cell Survival
MH  - Cytokines/biosynthesis
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Intestines/microbiology
MH  - Lipopolysaccharides/antagonists & inhibitors
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microbial Sensitivity Tests
MH  - Microscopy, Electron, Transmission
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Penaeidae/*chemistry
MH  - Peptide Fragments/*pharmacology
MH  - Pseudomonas Infections/*drug therapy/microbiology/mortality
MH  - *Pseudomonas aeruginosa/drug effects
MH  - RNA, Messenger/biosynthesis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sepsis/*drug therapy/microbiology/mortality
EDAT- 2007/03/28 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/03/28 09:00
PHST- 2006/10/03 00:00 [received]
PHST- 2007/01/08 00:00 [revised]
PHST- 2007/01/15 00:00 [accepted]
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - S1567-5769(07)00010-0 [pii]
AID - 10.1016/j.intimp.2007.01.006 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2007 May;7(5):687-700. doi: 10.1016/j.intimp.2007.01.006. 
      Epub 2007 Feb 7.